Skip to content
OpenCapital
Get started

Globus Medical GMED Reportable Segment — Other Research and Development Expense

Similar metrics at other companies

Madrigal Pharmaceuticals, Inc. logo
MDGLReportable Segment — Research and Development External Expense
$94.09M+2,166%
Incyte logo
INCYReportable Segment — Other research and development
$12.6M-18.7%
Madrigal Pharmaceuticals, Inc. logo
MDGLReportable Segment — Research ​And ​Development​ Expense, Personnel And Internal
$22.17M+3.2%
Insmed logo
INSMReportable Segment — R&D compensation and benefit-related expenses
$72.14M+34.7%
Guardant Health logo
GHReportable Segment — Research and development expense
$76.59M+2.3%
Summit Therapeutics logo
SMMTReportable Segment — R&D
$90.2M+148%

Other financials

Income statement

See full
Revenue$759.9M+27.0%
Gross profit$525.8M+30.6%
Operating income$150.4M+55.0%
Net income$124.3M+64.7%
EPS (diluted)$0.90+66.7%

Balance sheet

See full
Cash & equivalents$561.0M+21.6%
Total debt$116.3M+25.0%
Total equity$4.7B+15.8%
Total assets$5.4B+15.5%

Cash flow

See full
Operating cash flow$202.4M+14.1%
CapEx$39.6M+9.7%
Free cash flow$162.7M+15.3%

Valuation

See full
Market cap$10.76B+15.7%
Enterprise value$10.31B+15.6%
P/E18.3×-31.7×
P/S3.5×-0.2×

Profitability

See full
Gross margin67.9%+7.3pp
Operating margin17.2%+7.0pp
Net margin18.9%+11.5pp
FCF margin19.7%-1.1pp

Returns & leverage

See full
Return on equity13.3%+8.7pp
Debt / equity0×0.0×
Current ratio4.6×+0.1×

Where this comes from

Reported directly by Globus Medical in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The official record: Globus Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Globus Medical's reportable segment — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Globus Medical's reportable segment — other research and development expense?
Globus Medical (GMED) reported reportable segment — other research and development expense of $9.17M in Q1 2026.
How has Globus Medical's reportable segment — other research and development expense changed year-over-year?
Globus Medical's reportable segment — other research and development expense increased by 20.2% year-over-year, from $7.63M to $9.17M.
What does reportable segment — other research and development expense mean?
Non-payroll expenses related to research and development projects.
How do you interpret reportable segment — other research and development expense?
Higher spending often correlates with active clinical trials or new product development phases.
How does reportable segment — other research and development expense compare across companies?
Standard R&D overhead metric for companies with heavy clinical trial requirements.